Table 1.
Planned design of the interviews.
| Country classes | Country | Interview quota | Interview quota per stakeholder group* | Disease context** |
|---|---|---|---|---|
| Primary countries (with a 24 interviewee quota) |
Italy | 24 | 4 | Lung cancer |
| Romania | 24 | 4 | Cardiovascular disease | |
| Sweden | 24 | 4 | Rheumatoid arthritis | |
| United Kingdom | 24 | 4 | Muscular dystrophy | |
| Auxiliary countries (with a 12 interviewee quota) |
France | 12 | 2 | Lung cancer |
| Germany | 12 | 2 | Rheumatoid arthritis | |
| Netherlands | 12 | 2 | Muscular dystrophy | |
| United States | 12 | 2 | Cardiovascular disease |
*Six stakeholder groups were interviewed in every country. These stakeholder groups included the pharmaceutical and medical device industry, HTA/payers, regulators, academia, physicians, and the combined group of patient representatives, patients, and patients’ caregivers.
**Only for interviews with patients, patient representatives, caregivers, and physicians.